Abstract 4012: Patient perspective on the prevalence and severity of adverse psychosocial outcomes amongst those treated for lymphoma or chronic lymphocytic leukemia: An analysis of the Lymphoma Coalition’s 2024 Global Patient Survey

Abstract Patients who have received treatment for lymphoma or chronic lymphocytic leukemia (CLL) experience numerous side effects which can have a profound impact on health-related quality of life (HRQoL). Some of the most underreported are adverse psycho-social outcomes (APSO). We explored the prevalence and severity of APSO’s amongst a globally derived sample from this patient population. Patient reported outcomes (PRO’s) were collected from an anonymous global survey directed at patients with lymphoma and CLL. Nineteen different APSO’s were pre-specified in the survey. Prevalence was captured with severity assessed using a 5-part Likert scale. Latent class analysis (LCA) was used to cluster patients with a propensity for experiencing multiple APSO’s. Resultant clusters were investigated to determine if they were enriched for selected demographics. Responses were received from 5984 patients who had received treatment for lymphoma or CLL where the median age was 64, ranging from 18 - 94 years. Sixty percent were female. Fear of progression/relapse was the most prevalent APSO (49%; Table 1). Most APSO’s had severity scores above 3 indicating a moderate level of severity (Table 1). LCA identified a cluster comprising 12% of the patients who experienced all APSO’s at a higher rate than the remaining patients. Both younger age and female sex were significantly enriched in this cluster (p<0.0001). The results suggest that a segment of patients experience multiple APSO’s which can compound to create a significant overall degradation in HRQoL. While younger age and female sex are enriched in this segment, further exploration is needed to identify those with heightened risk for multiple APSO’s. The application of mitigation strategies in those suffering from APSO’s may help to improve patient’s HRQoL during treatment, recovery and rehabilitation. Psychosocial Outcome Prevalence (N = 5984) Severity Score (N) Fear of progression/relapse 49% 3.2 (2904) Concern relating to being immunocompromised 38.4% 3.2 (2281) Anxiety/nervousness 35% 3.1 (2067) Worry 33% 3.2 (1939) Concerns about physical appearance 27.4% 3.2 (1619) Depression/sadness 26.6% 3.1 (1567) Fear of dying 21.7% 3.3 (1279) Isolation of loneliness 21.5% 3.3 (1273) Loss of interest in usual activities 19.1% 3.3 (1125) Anger 18.5% 2.8 (1087) Loss of Self-Esteem 18.1% 3.2 (1071) Changes in relationships 16.8% 3.2 (994) Feelings of worthlessness 16.2% 3.3 (962) Grief or loss 15.7% 3.2 (929) Fear of being incapacitated 14.6% 3.4 (885) Loss of sense of purpose 12.2% 3.4 (719) PTSD 9.1% 3.2 (536) Changes in faith or beliefs 4.4% 3.3 (257) Conflicts between beliefs and cancer treatments 2.4% 3.3 (139) Other 2.4% 3.6 (132) None 18.4% N/A Citation Format: Steve E. Kalloger, Amanda Watson, Shawn Sajkowski, Lorna Warwick. Patient perspective on the prevalence and severity of adverse psychosocial outcomes amongst those treated for lymphoma or chronic lymphocytic leukemia: An analysis of the Lymphoma Coalition’s 2024 Global Patient Survey [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4012.